Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc to Discuss Partnership with Roche Holding AG for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy Call Transcript

Dec 23, 2019 / 01:30PM GMT
Release Date Price: $131.91 (+3.82%)
Operator

Good day, ladies and gentlemen, and welcome to the Sarepta Therapeutics Business Update Conference Call. (Operator Instructions) As a reminder, today's program is being recorded.

And now I'd like to introduce your host for today's program, Ian Estepan, Senior Vice President, Chief of Staff and Corporate Affairs. Please go ahead.

Ian M. Estepan
Sarepta Therapeutics, Inc. - Senior VP of Corporate Affairs & Chief of Staff

Thank you, Charl, and thank you all for joining today's call and happy holidays to all.

Earlier this morning, we issued a press release regarding a licensing agreement with Roche for rights to our micro-dystrophin gene therapy for Duchenne muscular dystrophy in territories outside the United States. The press release is available on our website at www.sarepta.com.

Joining us on the call today are Doug Ingram, Sandy Mahatme, Bo Cumbo, Dr. Gilmore O'Neill, and Dr. Louise Rodino-Klapac. After our formal remarks, we'll open the call for Q&A.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot